Risk of delays in commercializing the new product
First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2020.
The whole theme swung hardest in 2025: 4 of 7 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「The Group is working to develop new businesses by advancing its management plans and implementing various management strategies. However, if the commercialisation of new products does not progress as planned, this may affect the Group's operating results and other factors.」
The risk that new products may not be commercialised as planned continues to be disclosed. - FY2019RestatedAnnual report
「However, if the commercialisation of new products does not progress as planned, this may affect the company's financial position and operating results.」
The risk that new products may not be commercialised as planned continues to be disclosed. - FY2018RestatedAnnual report
「However, if the commercialisation of new products does not progress as planned, this may affect the company's financial position and operating results.」
The risk of delays in commercialising new products continues to be disclosed. - FY2017RestatedAnnual report
「However, if the commercialisation of new products does not progress as planned, this may affect the company's financial position and operating results.」
The risk of delays in commercialising new products continues to be disclosed. - FY2016First statedAnnual report
「The company is working to develop new businesses by advancing its medium-term business plan and implementing various management strategies. However, if the commercialisation of new products does not progress as planned, this may affect the company's financial position and operating results.」
The risk that new products may not be commercialised as planned is disclosed.